This CE activity was recorded from the live event "KY AETC Annual Conference: Caring for Vulnerable Populations" dated April 26-27, 2024. If you claimed credit for the live event you should not claim credit for this module.

Faculty

Needs Statement

According to the CDC 36,136 people received an HIV diagnosis in the United States and dependent areas in 2021. The annual number of new diagnoses decreased 7% from 2017 to 2021. It is critical for professionals to have current knowledge to provide effective treatment and education for patients. The CDC also states that Kentucky is at high risk for an HIV outbreak if introduced into the drug using population. HIV therapy was previously limited due to lack of treatment options, but more therapy options increase choice for patient treatment and challenges for providers. Screening for drug misuse is critical to the prevention of or early intervention in addiction. 

According to the CDC, in 2021, 43 states reported 107,300 new cases of chronic hepatitis C, which is 39.8 cases per 100,000 people. This number represents an 8% decrease from 2020, when there were 3.45 deaths per 100,000 people, and a 23% decrease from 2017, when there were 4.13 deaths per 100,000 people. 

 

Target Audience

Physicians, physician assistants, advanced practice nurses, nurses, pharmacists, dentists, social workers, health educators and therapists who currently provide or could provide care services to persons living with HIV/AIDS or Hepatitis C.

Objectives

Upon completion of this activity, participants will be able to:
1. Discuss the importance of screening for hepatitis B and C
2. Describe the work-up of patients living with hepatitis B or C
3. Recognize the principles and goals of antiviral therapy for hepatitis B and C

Accreditation

In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME
This enduring material is designated for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

IPE Competencies

• Values/Ethics for Interprofessional Practice
• Roles/ Responsibilities
• Interprofessional Communication

CPE
This knowledge-based activity will award 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

CDE
This online course meets regulatory requirements for 0.75 hours credit as permitted by 201 KAR 8:532 for dentists and 201 KAR 8:562 for dental hygienists.

ASWB ACE
As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 0.75 clinical continuing education credits.

CNE
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 nursing contact hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

Kristen Marks, MD, faculty for this event, is an independent contractor for Gilead Sciences.
 
All of the relevant financial relationships listed for these individuals have been mitigated.
 
The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Acknowledgment

This program is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U1OHA30535 as part of an award totaling $4.2m. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov.

“Funding for this presentation was made possible by cooperative agreement U1OHA30535 from the Health Resources and Services Administration HIV/AIDS Bureau. The views expressed do not necessarily reflect the official policies of the Department of Health and Human Services nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government. Any trade/brand names for products mentioned during this presentation are for training and identification purposes only.”

This content is owned by the AETC, and is protected by copyright laws.  Reproduction or distribution of the content without written permission of the sponsor is prohibited, and may result in legal action.